.png)
"For the patients, we must do better."
8th Annual Cell & Gene Therapy Innovation Leaders Summit 2025
10th & 11th September 2025
Hyatt Regency Barcelona Tower, Spain
The 8th Annual Cell and Gene Therapy Innovation Summit gathers C-suite executives, pioneering thought leaders, and leading academics who are dedicated to breaking down traditional silos and driving meaningful impact toward better patient outcomes.
As the field of cell and gene therapies rapidly advances, achieving equitable patient access will demand a strategic blend of AI-driven efficiencies, cross-sector collaboration, and a steadfast commitment to bridging the gap between groundbreaking science and practical healthcare delivery. This summit serves as a platform to propel these efforts forward, ensuring that innovative therapies reach the patients who need them most.
Uwe Gottschalk
Uwe Gottschalk is Chief Scientific Officer (CSO) at Lonza since July 2017. Between 2014 and 2017 he served as a Chief Technology Officer where he established and led the global Research and Technology organisation of Lonza Pharma/Biotech.
2025 Programme Snapshot
The 2025 CGTI programme will focus on solving key scale-up and manufacturing challenges in cell and gene therapies. It will showcase the latest strategies to drive costs down in scale-up, R&D and manufacturing, while exploring new innovations such as automation, AI and advanced technologies. We will also identify how partnerships and navigating the emerging regulatory frameworks can lead to a successful path to commercial viability.
Delegates will have invaluable access to our co-located drug discovery programme - #DDIF 2025
We are creating moments that matter!
KEY TOPICS
-
The REGENXBIO manufacturing Innovation Centre – a strategic Capability for AAV gene therapy
by REGENXBIO -
The power of resilience: the critical ingredient to moving innovative therapies forward
by Adverum Biotechnologies -
The promise of mRNA: a multifunctional platform addressing different therapeutic areas
by Moderna
VENDOR FOCUS
-
Cost reductions through innovative production, expression and yield
-
Scalability and manufacturing
-
Implementing AI/ML in CGT manufacturing
-
Digital and automation solutions for CGT Manufacturing
-
Patient-specific supply chains
-
CGT starting material solutions
-
Preserve, monitor, track, supply innovation
-
Single use and bioreactor innovation
Patients Journey
-
CXO sandbox: regulators, industry
-
Thought-provoking patient stories
-
Patient access in new markets such as APAC and the UAE
-
Integrating advanced tools for better patient outcomes
-
Making therapies affordable globally
-
Re-thinking standardisation at clinical sites
-
Product administration and material collection
SPEAKERS 2025
"It's not the destination, it's the journey."
WHY ATTEND
Exploring opportunities for small-scale CDMOs
Insights into key pain points such as shortage of talent and rising costs of supply chain
A deep dive into emerging biopharma pipelines and innovative emerging technologies
New innovations and strategies driving costs down and improving the manufacturing process
The promises and challenges of new therapeutic modalities
Leveraging innovation to bridge the gap from Gene to GMP
Executive training for commercial innovation and how to make a profitable growth
Navigating pricing, market access and reimbursement framework
Regulatory updates and compliance
INNOVATION SPOTLIGHT
-
Cell and gene therapies are poised to transform healthcare but how do we bridge the gap from lab to clinic
-
How can we deliver drugs more efficiently to patients
-
How AI can accelerate R&D for cell and gene therapies
-
From bench to bedside: navigating the scale-up journey
-
Building a robust supply chain. An overview of scale-up considerations and strategies
-
Insights into the accelerated approvals from US FDA
FIRESIDE CHAT (TBU)
-
Forced to discard or destroy up to 400 million doses
-
Experienced product quality could have been better. What are the solutions?
-
The team's reaction was not what did go wrong or why did it happen, no the question is -when do we do it again and let's hope it will be better.
-
What was the consequence of this experience?
IN PERSON - NETWORKING
-
Networking dinner offers an unparalleled opportunity for high-level executives and industry leaders to come together in an exclusive setting.
-
Pre-summit tour and dinner
-
Transport to and from venue location.
-
Available to a select group of attendees.
-
Pre-qualified one to one meetings
INVITE ONLY LEADERS SUMMIT
Benchmark with up to 200 decision makers in person only
SUMMIT INSIGHTS
200+
Up to 200 decision-makers in person. Previous attendee demographics include 50% EMEA, 30% America and 20% ROW
20%
20% best-of-breed vendors providing solutions to combat the manufacturing, scale-up & R&D hurdles of today's C>
06
Journey of CXO presentations. Six insightful, powerful and inspirational talks from CXOs in the industry
02
Exclusive in-person networking, over 2 days in Barcelona, on the 10th and 11th of September
7+
Pre-scheduled and pre-qualified one-to-one meetings with delegates who influence or make a decision
90%
Over 90% of our attendance provided positive feedback. Please click here to see what our delegation has to say
PREVIOUS SPEAKERS
ADVISORY
“Our very survival depends on our ability to stay awake, to adjust to new ideas, to remain vigilant and to face the challenge of change.” – Martin Luther King ...
LEADERS SHAPING THE FUTURE
ADVISORY
“Our very survival depends on our ability to stay awake, to adjust to new ideas, to remain vigilant and to face the challenge of change.” – Martin Luther King ...